By Bhanvi Satija (Reuters) -Drugmaker Sanofi said on Thursday it believes the impact from U.S. tariffs to be manageable as it ...

Q2 2025 Management View Paul Hudson, CEO, reported "another strong quarter with double-digit sales growth," attributing the ...

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

French pharmaceutical giant Sanofi reported a sharp increase in second-quarter profit on Thursday, driven by higher net sales ...

The pharmaceutical company’s top line grew faster than analysts expected for the second quarter due to drug launches and ...

For now, Sanofi’s U.S. inventory is insulating the company from a potential 15% tariff on drugs shipped from the EU.

Regeneron-partnered Dupixent, the crown jewel of Sanofi’s commercial portfolio, continued to impress with 21.1% sales growth ...

Arrowhead Pharmaceuticals strikes a $130M+ deal with Sanofi for plozasiran in Greater China, targeting high triglyceride ...

The French pharmaceutical company claims that Sarclisa-VRD showed great improvement in the minimum residual disease (MRD) ...

Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was revised upward.

FDA granted Orphan Drug Designation to Sanofi’s SAR446523, a monoclonal antibody targeting GPRC5D, for relapsed/refractory ...